Archive for the ‘biotech/medical’ category: Page 1553
Jun 21, 2020
Restaurants Are in Need of a Helping Hand. Miso Robotics Is Offering Them One. Literally
Posted by Kelvin Dafiaghor in categories: biotech/medical, employment, food, robotics/AI
Both are AI-enabled, allowing them to take in their surroundings and learn and evolve over time. They know what time to start cooking a well-done burger so that it’s done at exactly the same time as a medium-rare burger for the same order, or could learn how to optimize oil use to minimize waste, for instance.
In a pre-pandemic time of restaurant labor shortages, Flippy kept kitchen productivity high and costs low, a giant deal in an industry known for tiny margins. Introducing Flippy into a kitchen can increase profit margins by a whopping 300%, not to mention significantly reduce the stress managers feel when trying to fill shifts.
Jun 21, 2020
DARPA Invisible Man: Human Cells Engineered With Squid-Like Transparency
Posted by Quinn Sena in category: biotech/medical
Bioinspired research project a first step toward intrinsically translucent tissue.
Octopuses, squids and other sea creatures can perform a disappearing act by using specialized tissues in their bodies to manipulate the transmission and reflection of light, and now researchers at the University of California, Irvine have engineered human cells to have similar transparent abilities.
In a paper published today in Nature Communications, the scientists described how they drew inspiration from cephalopod skin to endow mammalian cells with tunable transparency and light-scattering characteristics.
Jun 21, 2020
3 thoughts on “Arrival of Gene-Edited Babies: What lies ahead?”
Posted by Genevieve Klien in categories: biotech/medical, ethics, genetics
By Valentina Lagomarsino figures by Sean Wilson
Nearly four months ago, Chinese researcher He Jiankui announced that he had edited the genes of twin babies with CRISPR. CRISPR, also known as CRISPR/Cas9, can be thought of as “genetic scissors” that can be programmed to edit DNA in any cell. Last year, scientists used CRISPR to cure dogs of Duchenne muscular dystrophy. This was a huge step forward for gene therapies, as the potential of CRISPR to treat otherwise incurable diseases seemed possible. However, a global community of scientists believe it is premature to use CRISPR in human babies because of inadequate scientific review and a lack of international consensus regarding the ethics of when and how this technology should be used.
Early regulation of gene-editing technology.
Jun 21, 2020
The brain’s functional organization slows down following a relationship breakup
Posted by Genevieve Klien in categories: biotech/medical, neuroscience
Summary: Findings reveal individual differences in the severity of depressive symptoms following a relationship breakdown are associated with changes in resting-state whole-brain dynamics.
Source: UPF Barcelona
During a person’s life, the experience of a stressful life event can lead to the development of depressive symptoms, even in a non-clinical population. For example, a relationship breakup is a fairly common event and is a powerful risk factor for quality of life, in addition to increasing the risk of a major depressive disorder.
Jun 21, 2020
The case for self-explainable AI
Posted by Genevieve Klien in categories: biotech/medical, information science, robotics/AI
For instance, suppose a neural network has labeled the image of a skin mole as cancerous. Is it because it found malignant patterns in the mole or is it because of irrelevant elements such as image lighting, camera type, or the presence of some other artifact in the image, such as pen markings or rulers?
Researchers have developed various interpretability techniques that help investigate decisions made by various machine learning algorithms. But these methods are not enough to address AI’s explainability problem and create trust in deep learning models, argues Daniel Elton, a scientist who researches the applications of artificial intelligence in medical imaging.
Elton discusses why we need to shift from techniques that interpret AI decisions to AI models that can explain their decisions by themselves as humans do. His paper, “Self-explaining AI as an alternative to interpretable AI,” recently published in the arXiv preprint server, expands on this idea.
Jun 21, 2020
New adjuvant successful in extending immunity against HIV
Posted by Omuterema Akhahenda in category: biotech/medical
Researchers at the Yerkes National Primate Research Center and the Emory Vaccine Center (EVC) are first to show a new adjuvant, 3M-052, helps induce long-lasting immunity against HIV. The study results are published today in Science Immunology.
In this pre–clinical study that included 90 rhesus monkeys, the researchers showed 3M-052, a new, synthetic small molecule that targets a specific receptor (TLR 7/8), successfully induced vaccine-specific, long-lived bone marrow plasma cells (BM-LLPCs), which are critical for durable immunity. In a striking observation, 3M-052-induced BM-LLPCs were maintained at high numbers for more than one year after vaccination. This prolonged interval is not only feasible in monitoring pre–clinical effectiveness, it is also highly informative in down selecting vaccine candidates.
First author Sudhir Pai Kasturi, Ph.D., an assistant professor in the Department of Pathology and Laboratory Medicine and a research assistant professor at Yerkes and the EVC, says, “We have known adjuvants are critical immunity-boosting supplements that help improve the effectiveness of vaccines. Until now, however, it has been unclear which class of adjuvants can promote stable and long-lived immunity in nonhuman primate models. Our study provides that information.”
Jun 20, 2020
Combining AI and biology could solve drug discovery’s biggest problems
Posted by Derick Lee in categories: biotech/medical, robotics/AI
There’s a lot of hope that artificial intelligence could help speed up the time it takes to make a drug and also increase the rate of success. Several startups have emerged to capitalize on this opportunity. But Insitro is a bit different from some of these other companies, which rely more heavily on machine learning than biology.
Machine learning can speed up the creation of new drugs and unlock the mysteries of major diseases, says Insitro CEO Daphne Koller.
[Photo: Ivan-balvan/iStock]
Continue reading “Combining AI and biology could solve drug discovery’s biggest problems” »
Jun 20, 2020
CRISPR-engineered T cells in patients with refractory cancer
Posted by Quinn Sena in categories: bioengineering, biotech/medical, genetics
:oooooo.
CRISPR-Cas9 is a revolutionary gene-editing technology that offers the potential to treat diseases such as cancer, but the effects of CRISPR in patients are currently unknown. Stadtmauer et al. report a phase 1 clinical trial to assess the safety and feasibility of CRISPR-Cas9 gene editing in three patients with advanced cancer (see the Perspective by Hamilton and Doudna). They removed immune cells called T lymphocytes from patients and used CRISPR-Cas9 to disrupt three genes (TRAC, TRBC, and PDCD1) with the goal of improving antitumor immunity. A cancer-targeting transgene, NY-ESO-1, was also introduced to recognize tumors. The engineered cells were administered to patients and were well tolerated, with durable engraftment observed for the study duration. These encouraging observations pave the way for future trials to study CRISPR-engineered cancer immunotherapies.